<DOC>
	<DOCNO>NCT01484912</DOCNO>
	<brief_summary>The objective study evaluate efficacy , pharmacological activity safety STA-2 treatment chronic stable angina .</brief_summary>
	<brief_title>Phase II Study STA-2 Patients With Chronic Stable Angina</brief_title>
	<detailed_description>The primary objective study evaluate efficacy STA-2 management chronic stable angina . The secondary objective study evaluate safety pharmacological activity STA-2 management chronic stable angina . This multi-center , double-blind , randomize , parallel-group , placebo-controlled study STA-2 management chronic stable angina . The study period patient approximately 7 week , patient undergone one-week screen washout period , follow 6 week treatment . Each patient require make total 5 visit . Primary Efficacy Endpoint : Change total exercise time . After washout , patient meet inclusion exclusion criterion randomly assign either treatment control group . The respective regimen : Treatment group : STA-2 250 mg capsule , contain 100 mg green tea polyphenols , 2 capsule ter die ( t.i.d.=three time daily ) 6 week , administer non-fasting state . Control group : Placebo 250 mg capsule , 2 capsule t.i.d . ( three time daily ) 6 week , administer non-fasting state .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female age &gt; 20 ; 2 . Patients effortinduced angina relieve rest nitroglycerin , catheterizationdocumented coronary artery disease previous myocardial infarction ≥ 3 month screen ; 3 . Patients manifest positive ETT ( exercise tolerance test ) ( define STsegment depression ≥ 1 mm compare rest , without limit angina ) screening ( Day 7 ) ; 4 . Patients manifest positive ETT ( exercise tolerance test ) ( define STsegment depression ≥ 1 mm compare rest , without limit angina ) day enrollment ( Day 0 ) . ETT performance Day 7 Day 0 require differ &gt; 20 % total exercise time ; 5 . Female patient postmenopausal stage childbearing potential : use adequate contraception since last menstruation plan conception study ; nonlactating ; negative pregnancy test ( urine ) within 14 day prior study ; 6 . Able provide write informed consent . Exclusion criterion : 1 . Patients preexcitation , conduction abnormality , pacemaker rhythm , unstable angina myocardial infarction within precede 3 month ; 2 . Patients heart failure ( New York Heart Association class III IV ) , uncorrected valvular congenital heart disease , patient need digoxin , isosorbide mononitrate , nitroglycerin sustain release preparation , theophylline , class I antiarrhythmic agent , digitalis , monoamine oxidase inhibitor , judge investigator ; 3 . Patients EKG abnormality prevent interpretation ischemia ( complete leave bundle branch block ) ; 4 . Patients Chronic Obstructive Pulmonary Disease ( COPD ) require bronchodilator ; 5 . Patients hepatic failure ( defined aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 3X upper limit normal value ) , and/or renal failure ( define serum creatinine &gt; 3 mg/dL ) ; 6 . Patients severe gastrointestinal illness judge investigator ; 7 . Patient condition interfere performance exercise tolerance test judge investigator ( e.g. , knee/ankle arthropathy , Parkinsonism , stroke ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Green tea polyphenols</keyword>
	<keyword>Chronic Stable Angina</keyword>
</DOC>